I would like to follow on to our great whip's very moving statement and ask our good friend Roscoe Bartlett, a distinguished Member from Maryland, whether or not he would pass a bill that would cut funding in the amount of $650 million for women, infant, and children out of the Department of Agriculture's program. {time} 1710 So in the four decades that I have served and have been honored to serve in this Congress, I believe that we will have reached an all-time low today if we pass a bill that will cut funding for the Department of Agriculture's Women, Infants, and Children program. Ladies and gentlemen, my brothers and sisters, how can anybody in Congress with a conscience seriously consider passing a bill, or even proposing one, that would result in more hunger for hundreds of thousands of the poorest and neediest low-income children across this Nation who are already suffering from hunger and malnutrition? I fail to understand the logic of any elected official who serves in Congress who would actually support a $650 million cut from the Women, Infants, and Children program during one of the worst economic downturns since the Great Depression without feeling some kind of moral or ethical guilt for doing so. The Women, Infants, and Children program serves nearly 10 million people each year and costs less than $100 per person.…
Share
More from John Conyers
I demand a recorded vote. The Acting CHAIR. Pursuant to clause 6 of rule XVIII, further proceedings on the amendment offered by the gentleman from Michigan will be postponed. Announcement by the Acting Chair The Acting CHAIR. Pursuant to…
I have an amendment at the desk. The Acting CHAIR. The Clerk will designate the amendment. The text of the amendment is as follows: Page 3, line 11, insert after ``settlement agreement'' the following: ``(except as provided in subsection…
Since the Trump administration has come into being, briefing requests submitted by Democratic Members' staff have been repeatedly denied, ignored, or delayed.
We should of course remain vigilant about pay-for-delay schemes, whereby branded drug manufacturers pay generic manufacturers to delay the entry of a version of branded drugs as the patent on the branded drug expires.





